Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review - Takeaways - MDSpire

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review

  • By

  • Bassam Muthanna

  • Aadhila Abbas Manthiri

  • Leen Haj Saleh

  • Abdulrahman F. Al-Mashdali

  • Shehab F. Mohamed

  • June 8, 2026

  • 0 min

Share

  • 1

    Tagraxofusp is a CD123-directed cytotoxin approved for treating adult blastic plasmacytoid dendritic cell neoplasm (BPDCN).

  • 2

    A systematic review included 27 studies with 343 adult patients treated with tagraxofusp, highlighting its efficacy and safety outcomes.

  • 3

    Overall response rates for tagraxofusp ranged from 65% to 90%, with complete response rates between 56% and 72% in clinical trials.

  • 4

    Capillary leak syndrome was identified as the primary toxicity associated with tagraxofusp, with varying incidence across studies.

  • 5

    Successful bridging to allogeneic hematopoietic stem cell transplantation significantly influenced long-term survival in BPDCN patients.

Original Source(s)

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review

  • by Bassam Muthanna, Aadhila Abbas Manthiri, Leen Haj Saleh, Abdulrahman F. Al-Mashdali, Shehab F. Mohamed

  • June 8, 2026

Related Content

Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression

An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial